A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

• Drug: Placebo
  
  Placebo solution + Placebo ALO-02 (intact)
• Drug: intact ALO-02 60 mg/7.2 mg
  
  Placebo solution + ALO-02 60 mg/7.2 mg (intact)
• Drug: crushed ALO-02 60 mg/7.2 mg
  
  crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
• Drug: crushed oxycodone IR 60 mg
  
  crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
• Drug: crushed ALO-02 40 mg/4.8 mg
  
  crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
• Drug: crushed oxycodone IR 40 mg
  
  crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)

• Placebo Comparator: Treatment A
  
  Intervention: Drug: Placebo
• Experimental: Treatment B
  
  Intervention: Drug: intact ALO-02 60 mg/7.2 mg
• Experimental: Treatment C
  
  Intervention: Drug: crushed ALO-02 60 mg/7.2 mg
• Active Comparator: Treatment D
  
  Intervention: Drug: crushed oxycodone IR 60 mg
• Experimental: Treatment E
  
  Intervention: Drug: crushed ALO-02 40 mg/4.8 mg
• Active Comparator: Treatment F
  
  Intervention: Drug: crushed oxycodone IR 40 mg

Inclusion Criteria:

• Healthy subjects.
• Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic purposes on at least 10 occassions within the last year before Screening Visit, and at least once in 8 weeks before the Screening Visit.

Exclusion Criteria:

• Diagnosis of substance and/or alcohol dependence.
• Subject has participated in, is currently participating in, or is seeking treatment for substance and/or alcohol related disorder.
• History of sleep apnea.
• Positive urine drug screen (UDS) for other that marijuana.
• Positive for Hepatitis B or C and HIV on Screening.